The Aim of this independent, parallel, twelve-week clinical study is to assess the efficacy of a commercially available oxygenated mouth rinse and mouth foam on both plaque level and gingival status in addition to assessing the oral health related quality of life.

Participants in all groups will be examined for gingival inflammation and plaque accumulation. The difference between three trial arms lies in the product used (control, oxygenated mouth wash, oxygenated mouth foam). A comparison against no intervention was disregarded due to ethical concerns (children only examined without informing them about their oral problems). After examination at baseline participants will be assigned to one arm of intervention. All participants will be provided an oral health education and gingival scaling to remove any underlining predisposing factor for gingival inflammation as well as fluoridated toothpaste and a toothbrush. Participants within intervention arms will also be provided the product package and informed how to use it (oxygenated mouth wash, oxygenated mouth foam).

All three arms will be followed after (1week, 2 weeks, 4 weeks, 8 weeks and 12 weeks) from baseline examination.

1. Control group Won't receive an oxygenated mouthwash nor oxygenated mouth foam (20 participants) 2. Intervention Group A: 20 participants - 2 oxygenated mouthwash bottle per individual for 3 months (40 bottles in total).

3. Intervention Group B: Oxygenated mouth foam/ day 20 participants- 2 oxygenated mouth foam bottle per individual for 3 months (40 bottles in total).

Inclusion Criteria:

• Students and employees at College of applied Medical science over 19 years old
• Both Saudis and non-Saudis.
• Students and employees consenting to participate.

Exclusion Criteria:

• Intern students or students in their 1st year.
• Students and employees with medically compromised condition (including congenital heart disease, hematological condition, immune deficiency condition and end stage renal disease or those with organ transplant within the previous 5 year.
• Students and employees not consenting to participate.

The principle investigator will be responsible for all data entry and management. Personal identification will be collected to regain contact with participants for the follow-up assessments and link baseline with follow-up data. This will be handled through pseudo anonymization, whereby the principle investigator will keep a separate file containing personal identifiable information for all participants and assign an identification code to each as they enter the study. Other than the examiner in the clinic everybody else will be working with coded data when analyzing the information.

upon the completion of the trial

study protocol as well as statistical analysis plane will be shared through a published paper as well as reporting back to trials.gov and clinical study report will be shared through trials.gov

due to ethical consideration participants cannot be blinded nor examiners as they will be providing oral hygiene instructions and information relative to using the mouth rinse and the mouth foam. everyone handling the data after examination will be blinded, they will be dealing with data obtained after identifying an identification code to each participant.